Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant

Cell Res. 2022 Apr;32(4):401-403. doi: 10.1038/s41422-022-00626-w. Epub 2022 Feb 14.

Na-Na Zhang^#^{1

2}, Rong-Rong Zhang^#¹, Yi-Fei Zhang^#^{1

3}, Kai Ji^#⁴, Xiao-Chuan Xiong^#^{1

5}, Qian-Shan Qin⁴, Peng Gao⁴, Xi-Shan Lu⁴, Hang-Yu Zhou⁶, Hai-Feng Song⁴, Bo Ying⁷, Cheng-Feng Qin^{8

9}

¹ Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.
² School of Medicine, Tsinghua University, Beijing, China.
³ Kunming University of Science and Technology, Kunming, Yunnan, China.
⁴ Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, China.
⁵ School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, Fujian, China.
⁶ Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
⁷ Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, China. bo.ying@abogenbio.com.
⁸ Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China. qincf@bmi.ac.cn.
⁹ Research Unit of Discovery and Tracing of Natural Focus Diseases, Chinese Academy of Medical Sciences, Beijing, China. qincf@bmi.ac.cn.

^# Contributed equally.

No abstract available

Publication types